Author:
Kornegoor Robert,Moelans Cathy B.,Verschuur-Maes Anoek H. J.,Hogenes Marieke C. H.,de Bruin Peter C.,Oudejans Joost J.,Marchionni Luigi,van Diest Paul J.
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Baak JP, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS (1991) Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest 64(2):215–223
2. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51
3. Rodriguez-Pinilla SM, Jones RL, Lambros MB, Arriola E, Savage K, James M, Pinder SE, Reis-Filho JS (2007) MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol 60(9):1017–1023. doi: jcp.2006.043869
4. Cho EY, Choi YL, Han JJ, Kim KM, Oh YL (2008) Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int 58(1):17–25
5. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70(5):2085–2094. doi: 0008-5472.CAN-09-3746
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献